Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells
Highlights • A Combination of erlotinib and dasatinib prevented the acquired resistance via EMT. • The acquired resistance mechanism of the combination therapy was T790 M mutation. • Preemptive combination therapy may be a promising strategy.
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-02, Vol.104, p.85-90 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 90 |
|---|---|
| container_issue | |
| container_start_page | 85 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 104 |
| creator | Sesumi, Yuichi Suda, Kenichi Mizuuchi, Hiroshi Kobayashi, Yoshihisa Sato, Katsuaki Chiba, Masato Masaki, Shimoji Tomizawa, Kenji Takemoto, Toshiki Mitsudomi, Tetsuya |
| description | Highlights • A Combination of erlotinib and dasatinib prevented the acquired resistance via EMT. • The acquired resistance mechanism of the combination therapy was T790 M mutation. • Preemptive combination therapy may be a promising strategy. |
| doi_str_mv | 10.1016/j.lungcan.2016.12.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1869968069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500216305803</els_id><sourcerecordid>1869968069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c570t-3e91097f96b6e3030865a0e87f120bf4500678d6e7286bf66db0015abb2bca9e3</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EokvhEUA-ckk6tonjXECo2pZKRUhQzpbtTLpesk7xJEh9exztwoELJ481_8z88w1jrwXUAoS-2Nfjku6DS7Us31rIGoR8wjbCtLIySsmnbFMSXdUAyDP2gmgPIFoB3XN2Jo0UCqDdsN12GDDMfBp478jNMUXPp8S3n--qA_bRzdiXIOxcinRYZRkp0uxSQO7uXUw08-311Vce0y76OE-ZSshXczysqswDjiO9ZM8GNxK-Or3n7PvV9u7yU3X75frm8uNtFZoW5kphVyy2Q6e9RgUKjG4coGkHIcEP78o2ujW9xlYa7Qete1_Wapz30gfXoTpnb499H_L0c0Ga7SHS6sAlnBaywuiu0wZ0V6TNURryRJRxsA85Hlx-tALsCtnu7QmyXSFbIW2BXOrenEYsvjD6W_WHahF8OAqwLPorYrYUIhYWfcwFtu2n-N8R7__pEMZymuDGH_iItJ-WnApFKyyVAvttvfR6aKEVNAaU-g3NjqSS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1869968069</pqid></control><display><type>article</type><title>Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Sesumi, Yuichi ; Suda, Kenichi ; Mizuuchi, Hiroshi ; Kobayashi, Yoshihisa ; Sato, Katsuaki ; Chiba, Masato ; Masaki, Shimoji ; Tomizawa, Kenji ; Takemoto, Toshiki ; Mitsudomi, Tetsuya</creator><creatorcontrib>Sesumi, Yuichi ; Suda, Kenichi ; Mizuuchi, Hiroshi ; Kobayashi, Yoshihisa ; Sato, Katsuaki ; Chiba, Masato ; Masaki, Shimoji ; Tomizawa, Kenji ; Takemoto, Toshiki ; Mitsudomi, Tetsuya</creatorcontrib><description>Highlights • A Combination of erlotinib and dasatinib prevented the acquired resistance via EMT. • The acquired resistance mechanism of the combination therapy was T790 M mutation. • Preemptive combination therapy may be a promising strategy.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2016.12.012</identifier><identifier>PMID: 28213007</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Acquired resistance ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Cell Line, Tumor - drug effects ; Cell Line, Tumor - metabolism ; Dasatinib ; Dasatinib - pharmacology ; Drug Resistance, Neoplasm ; Drug Therapy, Combination - methods ; Epithelial-mesenchymal transition ; Epithelial-Mesenchymal Transition - drug effects ; Epithelial-Mesenchymal Transition - genetics ; Erlotinib Hydrochloride ; Hematology, Oncology and Palliative Medicine ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Mutation ; Non-small cell lung cancer ; Protein Kinase Inhibitors - pharmacology ; Pulmonary/Respiratory ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Receptor, Epidermal Growth Factor - genetics ; Third- generation EGFR-TKI ; Treatment Outcome</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.85-90</ispartof><rights>2016 Elsevier Ireland Ltd</rights><rights>Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c570t-3e91097f96b6e3030865a0e87f120bf4500678d6e7286bf66db0015abb2bca9e3</citedby><cites>FETCH-LOGICAL-c570t-3e91097f96b6e3030865a0e87f120bf4500678d6e7286bf66db0015abb2bca9e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.lungcan.2016.12.012$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28213007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sesumi, Yuichi</creatorcontrib><creatorcontrib>Suda, Kenichi</creatorcontrib><creatorcontrib>Mizuuchi, Hiroshi</creatorcontrib><creatorcontrib>Kobayashi, Yoshihisa</creatorcontrib><creatorcontrib>Sato, Katsuaki</creatorcontrib><creatorcontrib>Chiba, Masato</creatorcontrib><creatorcontrib>Masaki, Shimoji</creatorcontrib><creatorcontrib>Tomizawa, Kenji</creatorcontrib><creatorcontrib>Takemoto, Toshiki</creatorcontrib><creatorcontrib>Mitsudomi, Tetsuya</creatorcontrib><title>Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Highlights • A Combination of erlotinib and dasatinib prevented the acquired resistance via EMT. • The acquired resistance mechanism of the combination therapy was T790 M mutation. • Preemptive combination therapy may be a promising strategy.</description><subject>Acquired resistance</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Cell Line, Tumor - drug effects</subject><subject>Cell Line, Tumor - metabolism</subject><subject>Dasatinib</subject><subject>Dasatinib - pharmacology</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drug Therapy, Combination - methods</subject><subject>Epithelial-mesenchymal transition</subject><subject>Epithelial-Mesenchymal Transition - drug effects</subject><subject>Epithelial-Mesenchymal Transition - genetics</subject><subject>Erlotinib Hydrochloride</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Mutation</subject><subject>Non-small cell lung cancer</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Pulmonary/Respiratory</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Third- generation EGFR-TKI</subject><subject>Treatment Outcome</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhi0EokvhEUA-ckk6tonjXECo2pZKRUhQzpbtTLpesk7xJEh9exztwoELJ481_8z88w1jrwXUAoS-2Nfjku6DS7Us31rIGoR8wjbCtLIySsmnbFMSXdUAyDP2gmgPIFoB3XN2Jo0UCqDdsN12GDDMfBp478jNMUXPp8S3n--qA_bRzdiXIOxcinRYZRkp0uxSQO7uXUw08-311Vce0y76OE-ZSshXczysqswDjiO9ZM8GNxK-Or3n7PvV9u7yU3X75frm8uNtFZoW5kphVyy2Q6e9RgUKjG4coGkHIcEP78o2ujW9xlYa7Qete1_Wapz30gfXoTpnb499H_L0c0Ga7SHS6sAlnBaywuiu0wZ0V6TNURryRJRxsA85Hlx-tALsCtnu7QmyXSFbIW2BXOrenEYsvjD6W_WHahF8OAqwLPorYrYUIhYWfcwFtu2n-N8R7__pEMZymuDGH_iItJ-WnApFKyyVAvttvfR6aKEVNAaU-g3NjqSS</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Sesumi, Yuichi</creator><creator>Suda, Kenichi</creator><creator>Mizuuchi, Hiroshi</creator><creator>Kobayashi, Yoshihisa</creator><creator>Sato, Katsuaki</creator><creator>Chiba, Masato</creator><creator>Masaki, Shimoji</creator><creator>Tomizawa, Kenji</creator><creator>Takemoto, Toshiki</creator><creator>Mitsudomi, Tetsuya</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170201</creationdate><title>Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells</title><author>Sesumi, Yuichi ; Suda, Kenichi ; Mizuuchi, Hiroshi ; Kobayashi, Yoshihisa ; Sato, Katsuaki ; Chiba, Masato ; Masaki, Shimoji ; Tomizawa, Kenji ; Takemoto, Toshiki ; Mitsudomi, Tetsuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c570t-3e91097f96b6e3030865a0e87f120bf4500678d6e7286bf66db0015abb2bca9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acquired resistance</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Cell Line, Tumor - drug effects</topic><topic>Cell Line, Tumor - metabolism</topic><topic>Dasatinib</topic><topic>Dasatinib - pharmacology</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drug Therapy, Combination - methods</topic><topic>Epithelial-mesenchymal transition</topic><topic>Epithelial-Mesenchymal Transition - drug effects</topic><topic>Epithelial-Mesenchymal Transition - genetics</topic><topic>Erlotinib Hydrochloride</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Mutation</topic><topic>Non-small cell lung cancer</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Pulmonary/Respiratory</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Third- generation EGFR-TKI</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sesumi, Yuichi</creatorcontrib><creatorcontrib>Suda, Kenichi</creatorcontrib><creatorcontrib>Mizuuchi, Hiroshi</creatorcontrib><creatorcontrib>Kobayashi, Yoshihisa</creatorcontrib><creatorcontrib>Sato, Katsuaki</creatorcontrib><creatorcontrib>Chiba, Masato</creatorcontrib><creatorcontrib>Masaki, Shimoji</creatorcontrib><creatorcontrib>Tomizawa, Kenji</creatorcontrib><creatorcontrib>Takemoto, Toshiki</creatorcontrib><creatorcontrib>Mitsudomi, Tetsuya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sesumi, Yuichi</au><au>Suda, Kenichi</au><au>Mizuuchi, Hiroshi</au><au>Kobayashi, Yoshihisa</au><au>Sato, Katsuaki</au><au>Chiba, Masato</au><au>Masaki, Shimoji</au><au>Tomizawa, Kenji</au><au>Takemoto, Toshiki</au><au>Mitsudomi, Tetsuya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>104</volume><spage>85</spage><epage>90</epage><pages>85-90</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><abstract>Highlights • A Combination of erlotinib and dasatinib prevented the acquired resistance via EMT. • The acquired resistance mechanism of the combination therapy was T790 M mutation. • Preemptive combination therapy may be a promising strategy.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>28213007</pmid><doi>10.1016/j.lungcan.2016.12.012</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.85-90 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1869968069 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Acquired resistance Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor - drug effects Cell Line, Tumor - metabolism Dasatinib Dasatinib - pharmacology Drug Resistance, Neoplasm Drug Therapy, Combination - methods Epithelial-mesenchymal transition Epithelial-Mesenchymal Transition - drug effects Epithelial-Mesenchymal Transition - genetics Erlotinib Hydrochloride Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Mutation Non-small cell lung cancer Protein Kinase Inhibitors - pharmacology Pulmonary/Respiratory Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Third- generation EGFR-TKI Treatment Outcome |
| title | Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A09%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20dasatinib%20on%20EMT-mediated-mechanism%20of%20resistance%20against%20EGFR%20inhibitors%20in%20lung%20cancer%20cells&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Sesumi,%20Yuichi&rft.date=2017-02-01&rft.volume=104&rft.spage=85&rft.epage=90&rft.pages=85-90&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2016.12.012&rft_dat=%3Cproquest_cross%3E1869968069%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1869968069&rft_id=info:pmid/28213007&rft_els_id=S0169500216305803&rfr_iscdi=true |